Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)

NCT04979468 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

440

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: DOVATO

Sponsor

Societa' Italiana Di Malattie Infettive E Tropicali